Krychtiuk, K., Wojdyla, D. M., Alexander, K. P., Goodman, S. G., Aronson, R. S., Windecker, S., … Lopes, R. D. (2024). GREATEST ABSOLUTE BENEFIT OF APIXABAN AND LIMITING ASPIRIN IS IN THOSE WITH COMORBIDITY: RESULTS FROM THE AUGUSTUS TRIAL. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 83, pp. 2234–2234).

Krychtiuk, Konstantin, Daniel M. Wojdyla, Karen P. Alexander, Shaun G. Goodman, Ronald S. Aronson, Stephan Windecker, Roxana Mehran, Christopher B. Granger, John H. Alexander, and Renato D. Lopes. “GREATEST ABSOLUTE BENEFIT OF APIXABAN AND LIMITING ASPIRIN IS IN THOSE WITH COMORBIDITY: RESULTS FROM THE AUGUSTUS TRIAL.” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 83:2234–2234, 2024.

Krychtiuk K, Wojdyla DM, Alexander KP, Goodman SG, Aronson RS, Windecker S, et al. GREATEST ABSOLUTE BENEFIT OF APIXABAN AND LIMITING ASPIRIN IS IN THOSE WITH COMORBIDITY: RESULTS FROM THE AUGUSTUS TRIAL. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024. p. 2234–2234.

Krychtiuk, Konstantin, et al. “GREATEST ABSOLUTE BENEFIT OF APIXABAN AND LIMITING ASPIRIN IS IN THOSE WITH COMORBIDITY: RESULTS FROM THE AUGUSTUS TRIAL.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 83, no. 13, 2024, pp. 2234–2234.

Krychtiuk K, Wojdyla DM, Alexander KP, Goodman SG, Aronson RS, Windecker S, Mehran R, Granger CB, Alexander JH, Lopes RD. GREATEST ABSOLUTE BENEFIT OF APIXABAN AND LIMITING ASPIRIN IS IN THOSE WITH COMORBIDITY: RESULTS FROM THE AUGUSTUS TRIAL. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024. p. 2234–2234.